Cargando…
Overexpression of C16orf74 is involved in aggressive pancreatic cancers
Clinical outcome of pancreatic ductal adenocarcinoma (PDAC) has not been improved in the last three decades due to the lack of effective molecular-targeted drugs. To identify a novel therapeutic target for PDAC, we have performed genome-wide anamysis and found that Homo sapiens chromosome 16 open re...
Autores principales: | Nakamura, Toru, Katagiri, Toyomasa, Sato, Shoki, Kushibiki, Toshihiro, Hontani, Koji, Tsuchikawa, Takahiro, Hirano, Satoshi, Nakamura, Yusuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584151/ https://www.ncbi.nlm.nih.gov/pubmed/28881575 http://dx.doi.org/10.18632/oncotarget.10912 |
Ejemplares similares
-
Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation
por: Sato, Shoki, et al.
Publicado: (2017) -
Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice
por: Takano, Hironobu, et al.
Publicado: (2015) -
Infrequent Mutation of the H‐Cadherin Gene on Chromosome 16q24 in Human Breast Cancers
por: Miki, Yoshio, et al.
Publicado: (1997) -
Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors
por: Hontani, Koji, et al.
Publicado: (2017) -
Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer
por: Tsuchikawa, Takahiro, et al.
Publicado: (2016)